arrow
I

Ignacio Romero

valencian institute of oncology (ivo) foundation
H指数:31
被引数:5,439

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer

PRIMA/ENGOT-OV26/GOG-3012试验中 niraparib 一线维持治疗新诊断晚期卵巢癌患者的患者报告结局更新及疾病进展对健康相关生活质量的影响

2026-07-010
OAAI
Morphological and molecular characterization of epithelial ovarian cancer: SEOM-SEAP consensus guidelines for biomarker integration in clinical practice

上皮卵巢癌的形态学和分子学特征:SEOM-SEAP关于生物标志物整合的临床实践共识指南

2026-05-010
PRE
Lenvatinib Plus Pembrolizumab in Participants With Advanced or Recurrent Endometrial Cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 Post-(Neo)Adjuvant Therapy Outcomes

Lenvatinib联合Pembrolizumab在晚期或复发性子宫内膜癌患者中的应用:Study 309/KEYNOTE-775和ENGOT-en9/LEAP-001术后(新辅助)治疗结局

2026-04-120
PRE
Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and/or BRCA2 mutation: Final overall survival results from the OPINION trial

在无胚系BRCA1和/或BRCA2突变且对铂类敏感的复发性卵巢癌患者中应用奥拉帕尼单药维持治疗:OPINION试验的最终总生存结果

2025-06-010
OAAI
Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancer

关于晚期卵巢癌维持治疗方案选择和护理模式的驱动因素共识

2025-04-190
OA
Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer
2024-08-010
PRE
Retrospective multicenter study of elderly patients with platinum-sensitive relapsed ovarian cancer treated with trabectedin and pegylated liposomal doxorubicin (pld) in a real-world setting: a geico study

在真实世界中,对接受trabectedin和聚乙二醇化脂质体阿霉素 (pld) 治疗的铂敏感复发性卵巢癌老年患者的回顾性多中心研究: geico研究

2024-07-050
OAAI
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

ESGO-ESMO-ESP共识会议关于卵巢癌的建议: 病理学和分子生物学以及早期,晚期和复发性疾病

2024-03-0146
OA
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
LANCET
IF88.5
2024-01-0155
OAAI
Tolerability and efficacy of trabectedin plus pegylated liposomal doxorubicin (PLD) in elderly patients with ovarian cancer (OC): GEICO 105-O study
2023-10-010
OA
Ventilatory Parameters in Obstetric Patients With COVID-19 and Impact of Delivery A Multicenter Prospective Cohort Study
CHEST
IF8.6
2023-03-018
OAAI
Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis

高级别卵巢癌中BRCA1和BRCA2突变位置与奥拉帕尼和贝伐单抗维持治疗获益的关系: III期PAOLA-1/ENGOT-ov25试验亚组探索性分析

2023-02-0118
OAAI
Laboratory Cross-Comparison and Ring Test Trial for Tumor BRCA Testing in a Multicenter Epithelial Ovarian Cancer Series: The BORNEO GEICO 60-0 Study
2022-11-042
OAAI
Clinical characteristics, respiratory management, and determinants of oxygenation in COVID-19 ARDS: A prospective cohort study
2022-10-0119
OAAI